B-cell Acute Lymphoblastic Leukemia: Clinical Trials

3 trials for B-cell Acute Lymphoblastic Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 recruiting. 3 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 33Recruiting 3
Phase 21Recruiting 1

Follow B-cell Acute Lymphoblastic Leukemia: new trials by email Literature Review of B-cell Acute Lymphoblastic Leukemia trials Research Report on B-cell Acute Lymphoblastic Leukemia

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
MK-1045, Blinatumomab, Acetaminophen - B-cell Acute Lymphoblastic Leukemia
Phase 2 / Phase 3RecruitingMerck Sharp & Dohme LLC3402026-05-182026-11-10
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
Fludarabine, Cyclophosphamide, CAR-T - B-cell Acute Lymphoblastic Leukemia
Phase 3RecruitingMemorial Sloan Kettering Cancer Center1302025-10-202026-11-12
Study of Out of Specification for Tisagenlecleucel
CTL019 - B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma
Phase 3RecruitingNovartis Pharmaceuticals2002019-11-212026-09-15

Narrower conditions

Burkitt Lymphoma (3)  ·  Lymphoma, Large B-Cell, Diffuse (1)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)  ·  Recurrence (1)

Broader conditions

DNA Virus Infections (3)  ·  Epstein-Barr Virus Infections (3)  ·  Hemic and Lymphatic Diseases (3)  ·  Herpesviridae Infections (3)  ·  Immune System Diseases (3)  ·  Immunoproliferative Disorders (3)  ·  Infections (3)  ·  Lymphatic Diseases (3)  ·  Lymphoma (3)  ·  Lymphoma, B-Cell (3)  ·  Lymphoma, Non-Hodgkin (3)  ·  Lymphoproliferative Disorders (3)  ·  Neoplasms (3)  ·  Neoplasms by Histologic Type (3)  ·  Tumor Virus Infections (3)

Interventions

Acetaminophen (1)  ·  Cyclophosphamide (1)  ·  Dexamethasone (1)  ·  Diphenhydramine (1)  ·  blinatumomab (1)  ·  fludarabine (1)  ·  siltuximab (1)  ·  tisagenlecleucel (1)  ·  tocilizumab (1)

Sponsors

Memorial Sloan Kettering Cancer Center (1)  ·  Merck Sharp & Dohme LLC (1)  ·  Novartis Pharmaceuticals (1)

Countries

Canada (2)  ·  Japan (2)  ·  Netherlands (2)  ·  Denmark (1)  ·  France (1)  ·  Germany (1)  ·  Greece (1)  ·  Israel (1)  ·  Italy (1)  ·  Spain (1)  ·  Sweden (1)  ·  United States (1)

Top investigators

Kevin Curran, MD (1)

NIH funding

2025 (1)